These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 12438832)

  • 1. Role of invasive EP testing in the evaluation and management of hypertrophic cardiomyopathy.
    Behr ER; Elliott P; McKenna WJ
    Card Electrophysiol Rev; 2002 Dec; 6(4):482-6. PubMed ID: 12438832
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of hypertrophic cardiomyopathy in children.
    Seggewiss H; Rigopoulos A
    Paediatr Drugs; 2003; 5(10):663-72. PubMed ID: 14510624
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy.
    Maron BJ; Spirito P; Shen WK; Haas TS; Formisano F; Link MS; Epstein AE; Almquist AK; Daubert JP; Lawrenz T; Boriani G; Estes NA; Favale S; Piccininno M; Winters SL; Santini M; Betocchi S; Arribas F; Sherrid MV; Buja G; Semsarian C; Bruzzi P
    JAMA; 2007 Jul; 298(4):405-12. PubMed ID: 17652294
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survival after cardiac arrest or sustained ventricular tachycardia in patients with hypertrophic cardiomyopathy.
    Elliott PM; Sharma S; Varnava A; Poloniecki J; Rowland E; McKenna WJ
    J Am Coll Cardiol; 1999 May; 33(6):1596-601. PubMed ID: 10334430
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic determinants in hypertrophic cardiomyopathy. Prospective evaluation of a therapeutic strategy based on clinical, Holter, hemodynamic, and electrophysiological findings.
    Fananapazir L; Chang AC; Epstein SE; McAreavey D
    Circulation; 1992 Sep; 86(3):730-40. PubMed ID: 1516184
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Spectrum and prognostic significance of arrhythmias on ambulatory Holter electrocardiogram in hypertrophic cardiomyopathy.
    Adabag AS; Casey SA; Kuskowski MA; Zenovich AG; Maron BJ
    J Am Coll Cardiol; 2005 Mar; 45(5):697-704. PubMed ID: 15734613
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk Markers and Appropriate Implantable Defibrillator Therapy in Hypertrophic Cardiomyopathy.
    Magnusson P; Gadler F; Liv P; Mörner S
    Pacing Clin Electrophysiol; 2016 Mar; 39(3):291-301. PubMed ID: 26681505
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low occurrence of ventricular arrhythmias after alcohol septal ablation in high-risk patients with hypertrophic obstructive cardiomyopathy.
    Rigopoulos AG; Daci S; Pfeiffer B; Papadopoulou K; Neugebauer A; Seggewiss H
    Clin Res Cardiol; 2016 Nov; 105(11):953-961. PubMed ID: 27270758
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypertrophic cardiomyopathy: evaluation and treatment of patients at high risk for sudden death.
    Fananapazir L; McAreavey D
    Pacing Clin Electrophysiol; 1997 Feb; 20(2 Pt 2):478-501. PubMed ID: 9058851
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevention of sudden cardiac death with implantable cardioverter-defibrillators in children and adolescents with hypertrophic cardiomyopathy.
    Maron BJ; Spirito P; Ackerman MJ; Casey SA; Semsarian C; Estes NA; Shannon KM; Ashley EA; Day SM; Pacileo G; Formisano F; Devoto E; Anastasakis A; Bos JM; Woo A; Autore C; Pass RH; Boriani G; Garberich RF; Almquist AK; Russell MW; Boni L; Berger S; Maron MS; Link MS
    J Am Coll Cardiol; 2013 Apr; 61(14):1527-35. PubMed ID: 23500286
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic Implications of Nonsustained Ventricular Tachycardia in High-Risk Patients With Hypertrophic Cardiomyopathy.
    Wang W; Lian Z; Rowin EJ; Maron BJ; Maron MS; Link MS
    Circ Arrhythm Electrophysiol; 2017 Mar; 10(3):. PubMed ID: 28314849
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sudden death and hypertrophic cardiomyopathy: a review.
    Ly HQ; Greiss I; Talakic M; Guerra PG; Macle L; Thibault B; Dubuc M; Roy D
    Can J Cardiol; 2005 Apr; 21(5):441-8. PubMed ID: 15861263
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of implantable cardioverter defibrillator therapy for primary and secondary prevention of sudden cardiac death in hypertrophic cardiomyopathy.
    Begley DA; Mohiddin SA; Tripodi D; Winkler JB; Fananapazir L
    Pacing Clin Electrophysiol; 2003 Sep; 26(9):1887-96. PubMed ID: 12930505
    [TBL] [Abstract][Full Text] [Related]  

  • 14. QRS Fragmentation and QTc Duration Relate to Malignant Ventricular Tachyarrhythmias and Sudden Cardiac Death in Patients with Hypertrophic Cardiomyopathy.
    Debonnaire P; Katsanos S; Joyce E; VAN DEN Brink OV; Atsma DE; Schalij MJ; Bax JJ; Delgado V; Marsan NA
    J Cardiovasc Electrophysiol; 2015 May; 26(5):547-55. PubMed ID: 25648421
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Sudden cardiac death in familial hypertrophic cardiomyopathy. Identification of high-risk patients].
    Pellnitz C; Geier C; Perrot A; Dietz R; Osterziel KJ; Haverkamp W
    Dtsch Med Wochenschr; 2005 May; 130(18):1150-4. PubMed ID: 15856398
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Interventional treatment in hypertrophic cardiomyopathy].
    Gietzen FH; Schümmelfeder J; Neuser H; Brunn J; Schumacher B; Kerber S
    Herz; 2005 Mar; 30(2):102-10. PubMed ID: 15875098
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Outcomes in Patients With Nonobstructive, Labile, and Obstructive Hypertrophic Cardiomyopathy.
    Lu DY; Pozios I; Haileselassie B; Ventoulis I; Liu H; Sorensen LL; Canepa M; Phillip S; Abraham MR; Abraham TP
    J Am Heart Assoc; 2018 Feb; 7(5):. PubMed ID: 29478967
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Course and Quality of Life in High-Risk Patients With Hypertrophic Cardiomyopathy and Implantable Cardioverter-Defibrillators.
    Maron BJ; Casey SA; Olivotto I; Sherrid MV; Semsarian C; Autore C; Ahmed A; Boriani G; Francia P; Winters SL; Giudici M; Koulova A; Garberich R; Rowin EJ; Sears SF; Maron MS; Spirito P
    Circ Arrhythm Electrophysiol; 2018 Apr; 11(4):e005820. PubMed ID: 29625970
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Evaluation of the risk of sudden death in hypertrophic cardiomyopathy].
    Sadoul N; de Chillou C; Aliot E; McKenna WJ
    Arch Mal Coeur Vaiss; 1999 Apr; 92 Spec No 1():65-73. PubMed ID: 10326160
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Electrophysiologic abnormalities in patients with hypertrophic cardiomyopathy. A consecutive analysis in 155 patients.
    Fananapazir L; Tracy CM; Leon MB; Winkler JB; Cannon RO; Bonow RO; Maron BJ; Epstein SE
    Circulation; 1989 Nov; 80(5):1259-68. PubMed ID: 2805263
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.